Angstrom Pharmaceuticals, Inc.
Angstrom Pharmaceuticals, Inc. release
Angstrom Pharmaceuticals, Inc. 26.10.2011 16:58 --------------------------------------------------------------------------- Angstrom Pharmaceuticals Announces Publication of the Discovery of the Cellular Target of Its A6 Phase II Clinical Compound Resulting From Its Joint Study With Apricus Biosciences Preclinical Results Elucidate the Mechanism of Action of A6 Peptide in Blocking Cancer Cell Migration SAN DIEGO, 2011-10-26 16:42 CEST (GLOBE NEWSWIRE) -- Angstrom Pharmaceuticals, Inc. ('Angstrom' or the 'Company') announced today that the Molecular Cancer Therapeutic Journal, a peer reviewed journal, has published results elucidating the cellular target of its A6 phase II compound. The collaborative effort between Apricus Biosciences, Inc. (Nasdaq:APRI) ('Apricus Bio') and Angstrom resulted in the discovery of the mechanism of action by which Angstrom's A6 peptide blocks the migration of CD44-expressing cancer cells. Angstrom previously reported that results from a pharmacokinetic pre-clinical study showed significant improvement in the delivery and half life of A6, a proprietary peptide treatment for ovarian cancer that was in Phase II development by Angstrom. Specifically, the Company reported at that time that the incorporation of Apricus Bio's NexACT(R) technology enabled the dose of A6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model. Dr. Malcolm Finlayson, President and Chief Executive Officer of Angstrom, commented, 'This study elucidates the mechanism of action and the cellular target of the A6 peptides in blocking cancer cell migration and we believe, when examined with the previous pre-clinical results we published in 2010 with Apricus Bio, demonstrate that their proprietary NexACT(R) technology can play an important role in the subcutaneous delivery of peptide drugs. We look forward to continuing to work with Apricus Bio to develop a product or products in the peptide field that can take advantage of NexACT(R)'s apparently positive effect in this area.' The abstract to the study is available and can be accessed at the following site: mct.aacrjournals.org/content/early/2011/08/31/1535-7163.MCT-11-0351.abstract. About Angstrom's A6 Peptide Technology A6 is in clinical development for ovarian cancer and in preclinical development for the treatment of diabetic retinopathy and age-related macular degeneration. A6 binds to the cell surface receptor CD44 and inhibits cancer cell migration. The IC50 for A6 inhibition of chemotaxis in several human cancer cell lines is in the nM-pM range indicating a physiologically relevant mechanism. Furthermore the inhibition of cancer cell migration persists for 18-20 hours following the removal of A6. A6 is stable in phosphate buffer for more than 5 years when stored 2-8°C. A6 has been shown to have no dose-limiting toxicity in animal studies and consistently demonstrates an excellent safety profile across animal studies and human trials. The Company has recently completed a placebo-controlled Phase 2 clinical trial evaluating A6 in women with biochemical recurrent ovarian cancer. In this study, the time to tumor progression was doubled in patients receiving A6 over that of placebo control (p<0.01). A second Phase 2 clinical trial in patients with persistent or recurrent ovarian cancer is in progress. This trial is being conducted by the Gynecological Oncology Group (NCI) and the translational research component of this study will assess CD44 as a biomarker About Angstrom Pharmaceuticals Angstrom Pharmaceuticals, Inc., a privately held pharmaceutical company headquartered in San Diego, California, is developing a new class of proprietary drugs that treat diseases involving cell migration, invasion, and metastasis. Angstrom's lead product, A6 peptide, is a First-in-Class 'Oncoparalytic', stopping tumors from metastasizing by paralyzing cancer cells. For further information, go to www.angstrominc.com/ Angstrom Pharmaceuticals' Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. CONTACT: Angstrom Pharmaceuticals, Inc. Dr. Malcolm Finlayson Chief Executive Officer 990 Highland Drive, Suite 314 Solana Beach, CA 92075 Telephone: (858) 314-2356 Fax: (858) 314-2355 News Source: NASDAQ OMX 26.10.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Angstrom Pharmaceuticals, Inc. United States Phone: Fax: E-mail: Internet: ISIN: US9901789803 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found